After a momentous 2024, Culver City-based ImmunityBio Inc., the immunotherapy company founded and majority-owned by ...

Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...

ImmunityBio, Inc. (NASDAQ:IBRX), a $2.37 billion biotechnology firm specializing in biological products, has disclosed new ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

CULVER CITY, Calif., February 13, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunity therapy company, today announced the Medicines and Healthcare products Regulatory Agency (MHRA ...

Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...

(RTTNews) - ImmunityBio, Inc. (IBRX), a immunotherapy company, provided a regulatory update on its clinical development pipeline following discussions with the U.S. Food and Drug Administration or ...

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Friday,Benzinga reports. They currently have a $30.00 price target on the stock.

ImmunityBio (IBRX) announced the Medicines and Healthcare products Regulatory Agency has validated and accepted the marketing authorization ...

CULVER CITY, Calif., February 19, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded ...